Physician profile
Barry A Sarkell
NPI 1861459497
$8,543.02
in general payments reported to CMS, 2019-2025
26 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $379 · 2021: $1,464 · 2022: $1,264 · 2023: $1,276 · 2024: $1,440 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,310 · Education: $41.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.54 |
| Education | $41.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,282.03 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $981.37 | 2019-2025 | |
| Ucb, INC. | $645.00 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $578.56 | 2020-2025 | Tremfya |
| Leo Pharma INC. | $516.84 | 2020-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $468.94 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $445.54 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $407.15 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $357.24 | 2019-2025 | |
| Amgen INC. | $352.59 | 2019-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.66 | 2022-2025 | Spevigo |
| Incyte Corporation | $249.87 | 2021-2025 | Opzelura |
| Pfizer INC. | $234.73 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $160.84 | 2019-2025 | Blu-U, Ilumya |
| Dermavant Sciences, INC. | $158.23 | 2023-2024 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $117.21 | 2023-2024 | Sotyktu |
| Biofrontera INC. | $69.47 | 2019-2025 | Ameluz |
| Almirall LLC | $35.65 | 2019-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $34.55 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $32.68 | 2019 | |
| Celgene Corporation | $29.25 | 2019 | |
| Strata Skin Sciences, INC. | $28.56 | 2025 | Xtrac |
| Verrica Pharmaceuticals INC. | $24.72 | 2023 | Ycanth |
| Misonix INC | $22.68 | 2021 | |
| Mayne Pharma Commercial LLC | $21.23 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.43 | 2024 | Jublia, Cabtreo, Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Sarkell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.